Effect of topical corticosteroids on the recovery of histamine releasing factors in nasal washings of patients with allergic rhinitis. A double-blind, randomized, placebo-controlled study.
Nasal washings (NW) have been used by many investigators as a readily available biologic fluid for studying the mechanism of allergic reactions. These fluids have been analyzed for the presence of various mediators, including cytokines. Recently, histamine releasing factors (HRF) have been detected in the NW. The objective of this study was to investigate the effect of treatment with topical corticosteroids on the recovery of these cytokines from the NW obtained from patients with allergic rhinitis. A group of 30 patients with ragweed pollen allergy were given either beclomethasone dipropionate (BDP) or placebo for 1 wk in a double-blind randomized manner. NW were performed twice before the start of the treatment period and were repeated twice at the end of the study. HRF activity was measured in the NW. Patients maintained a daily symptom score. The activity of HRF decreased significantly (mean +/- SD, pre = 37.2 +/- 21.3% versus post = 23.8 +/- 20.1%; p less than 0.01) in the BDP group, as did the mean symptom score (5.1 +/- 1.4 versus 1.5 +/- 1.5, p less than 0.01) at the end of the treatment period. In contrast, there was no significant change in HRF recovery (32.8 +/- 25.6% versus 33.8 +/- 25.3%; p less than 0.05) or symptom score (4.8 +/- 1.8 versus 5.4 +/- 1.9; p greater than 0.05) in the placebo group. There was a significant correlation between the net changes in symptom scores and the net differences in HRF activity. We speculate that the reduction in HRF in the nasal mucosa may contribute to the clinical efficacy of topical corticosteroids.(ABSTRACT TRUNCATED AT 250 WORDS)
Sim
T C
TC
Department of Internal Medicine, University of Texas Medical Branch, Galveston 77550.
Hilsmeier
K A
KA
Alam
R
R
Allen
R K
RK
Lett-Brown
M A
MA
Grant
J A
JA
D000328:Adult; D000336:Aerosols; D001507:Beclomethasone / Q000008:administration & dosage / Q000627:therapeutic use*; D016207:Cytokines / Q000032:analysis*; D004311:Double-Blind Method; D005260:Female; D006636:Histamine Release / Q000187:drug effects*; D006801:Humans; D008297:Male; D009297:Nasal Mucosa / Q000276:immunology*; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*; D007507:Therapeutic Irrigation
D000336:Aerosols; D016207:Cytokines; D001507:Beclomethasone